Quick Answer
Processa Pharmaceuticals, Inc. reported Stockholders Equity of $5.58 million for fiscal year 2025.
Processa Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.58M | +228.8% |
| 2024 | $1.70M | -66.0% |
| 2023 | $4.99M | -33.2% |
| 2022 | $7.47M | -70.7% |
| 2021 | $25.49M | +11.1% |
| 2020 | $22.94M | +186.3% |
| 2019 | $8.01M | -17.4% |
| 2018 | $9.70M | +2499.7% |
| 2017 | $373.2K | +116.5% |
| 2016 | -$2.27M | -2545.4% |
| 2015 | -$85.7K | -107.1% |
| 2014 | $1.21M | -27.7% |
| 2013 | $1.67M | -34.8% |
| 2012 | $2.56M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.83M | +56.8% | -4.5% |
| June 30, 2025 | $6.11M | +1.4% | +73.2% |
| March 31, 2025 | $3.53M | -60.3% | +107.9% |
| December 31, 2024 | $1.70M | -66.0% | -54.4% |
| September 30, 2024 | $3.72M | -48.1% | -38.2% |
| June 30, 2024 | $6.02M | -34.2% | -32.2% |
| March 31, 2024 | $8.88M | -12.4% | +78.1% |
| December 31, 2023 | $4.99M | -33.2% | -30.4% |
- Processa Pharmaceuticals, Inc. showed an increase of +228.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, Processa Pharmaceuticals, Inc.’s stockholders equity has grown by 117.7% (from $2.56 million to $5.58 million).
- The most recent figure is from Processa Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: